trial · primary record
Trastuzumab + Durvalumab + FLOT
Gastric Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2030-12-31 |
| Primary endpoint | Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0 |
| Registry ID | NCT07911280 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:54.465Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07911280
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.